Can 'Peacekeeper' cells stop diabetes in its tracks?

NCT ID NCT05207995

Completed Disease control Sponsor: Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested whether a new type of immune cell, called a tolerogenic dendritic cell, is safe for people with type 1 diabetes. The cells were made from each patient's own blood and designed to calm the immune system attack on the pancreas. 32 participants received the cells or standard care, and researchers monitored blood sugar, insulin markers, and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tolerogenic dendritic cells (immune cells trained to calm the immune system)
What this could lead to: If successful, this approach could point toward a way to preserve insulin production in type 1 diabetes without lifelong immune suppression.
What could go wrong: This is an early-phase safety study with only 32 participants. It is not designed to prove effectiveness, and the treatment may not work or may have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS

Contacts and locations

Locations

Healthcare institution "Minsk City Clinical Endocrinology Center"

Minsk, 220000, Belarus

More trials for these conditions

Other studies related to the condition(s) this trial covers.